Total Payments
$322,427
2024 Payments
$29,704
Companies
28
Transactions
208
Medicare Patients
391
Medicare Billing
$96,642
Payment Breakdown by Category
Consulting$208,373 (64.6%)
Research$78,463 (24.3%)
Travel$17,592 (5.5%)
Other$14,608 (4.5%)
Food & Beverage$3,383 (1.0%)
Education$8.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $208,373 | 97 | 64.6% |
| Unspecified | $78,463 | 12 | 24.3% |
| Travel and Lodging | $17,592 | 29 | 5.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,703 | 7 | 3.0% |
| Honoraria | $4,905 | 2 | 1.5% |
| Food and Beverage | $3,383 | 60 | 1.0% |
| Education | $8.03 | 1 | 0.0% |
Payments by Type
General
$243,963
196 transactions
Research
$78,463
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $94,919 | 71 | $0 (2024) |
| MacroGenics, Inc. | $71,609 | 4 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $24,507 | 21 | $0 (2024) |
| Amgen Inc. | $13,204 | 4 | $0 (2023) |
| EMD Serono, Inc. | $11,893 | 5 | $0 (2022) |
| Janssen Biotech, Inc. | $11,511 | 11 | $0 (2024) |
| Janssen Research & Development, LLC | $11,167 | 9 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $9,399 | 6 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $9,242 | 5 | $0 (2017) |
| PFIZER INC. | $9,110 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,704 | 34 | Janssen Scientific Affairs, LLC ($12,538) |
| 2023 | $37,139 | 29 | AstraZeneca Pharmaceuticals LP ($6,551) |
| 2022 | $22,099 | 16 | EMD Serono, Inc. ($5,268) |
| 2021 | $119,733 | 27 | MacroGenics, Inc. ($71,609) |
| 2020 | $44,977 | 27 | AstraZeneca Pharmaceuticals LP ($23,159) |
| 2019 | $13,587 | 13 | AstraZeneca Pharmaceuticals LP ($8,001) |
| 2018 | $25,108 | 37 | AstraZeneca Pharmaceuticals LP ($17,473) |
| 2017 | $30,080 | 25 | Millennium Pharmaceuticals, Inc. ($9,242) |
All Payment Transactions
208 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | BRAFTOVI (Drug), VIZIMPRO, LORBRENA | — | In-kind items and services | $3,200.00 | Research |
| Study: BRAFTOVI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $58.18 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $205.50 | General |
| 11/12/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 10/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 09/24/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 09/20/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 09/12/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 09/10/2024 | PFIZER INC. | XALKORI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: XALKORI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/08/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/07/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/07/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $68.96 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 08/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $275.00 | General |
| 08/07/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,467.96 | General |
| 06/28/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Eli Lilly and Company | — | — | In-kind items and services | $689.44 | Research |
| Study: SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | ||||||
| 06/24/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $155.00 | General |
| 06/01/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $120.60 | General |
| 06/01/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $8.40 | General |
| 05/31/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $65.13 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | MacroGenics, Inc. | $70,234 | 3 |
| BRAFTOVI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| XALKORI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | Eli Lilly and Company | $689.44 | 1 |
| A Phase III, Open-Label, Randomized Study of Atezolizumab MPDL3280A, Anti-Pd-L1 Antibody in Combination With Carboplatin or Cisplatin Pemetrexed Compared With Carboplatin or Cisplatin Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer | F. Hoffmann-La Roche AG | $425.79 | 1 |
| LORLATINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| All Comers SSF | F. Hoffmann-La Roche AG | $230.94 | 1 |
| A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | Seattle Genetics, Inc. | $97.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 91 | 262 | $124,794 | $27,617 |
| 2022 | 3 | 96 | 246 | $117,524 | $27,201 |
| 2021 | 3 | 90 | 246 | $113,866 | $26,720 |
| 2020 | 4 | 114 | 215 | $62,788 | $15,104 |
Total Patients
391
Total Services
969
Medicare Billing
$96,642
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 58 | 228 | $108,984 | $24,111 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $10,285 | $2,311 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 17 | $5,525 | $1,194 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 201 | $96,480 | $22,749 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 23 | 23 | $13,938 | $3,130 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 22 | $7,106 | $1,322 | 18.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 55 | 186 | $89,838 | $20,905 | 23.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 44 | $14,300 | $3,535 | 24.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $9,728 | $2,280 | 23.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 42 | 81 | $28,836 | $7,077 | 24.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 32 | 72 | $18,144 | $4,151 | 22.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $8,100 | $2,000 | 24.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 25 | 47 | $7,708 | $1,876 | 24.3% |
About Dr. Rachel Sanborn, MD
Dr. Rachel Sanborn, MD is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275548794.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rachel Sanborn, MD has received a total of $322,427 in payments from pharmaceutical and medical device companies, with $29,704 received in 2024. These payments were reported across 208 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($208,373).
As a Medicare-enrolled provider, Sanborn has provided services to 391 Medicare beneficiaries, totaling 969 services with total Medicare billing of $96,642. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Portland, OR
- Active Since 07/31/2006
- Last Updated 10/19/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275548794
Products in Payments
- TAGRISSO (Drug) $67,105
- RYBREVANT (Drug) $17,168
- IMFINZI (Drug) $15,909
- LIBTAYO (Biological) $10,980
- IMFINZI (Biological) $10,961
- ALUNBRIG (Drug) $9,242
- Alecensa (Biological) $7,467
- BRAFTOVI (Drug) $6,900
- Tepotinib $4,025
- COSELA (Drug) $3,617
- Avastin (Biological) $3,250
- Oncology Testing (Device) $2,782
- Tepmetko (Drug) $2,600
- Enhertu (Drug) $1,791
- Trodelvy (Drug) $1,480
- XALKORI (Drug) $940.00
- Tecentriq (Biological) $656.73
- TECENTRIQ (Biological) $503.47
- LORBRENA (Drug) $330.00
- OPDIVO (Biological) $23.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Jay Andersen, M.d, M.D
Hematology & Oncology — Payments: $480,702
Hematology & Oncology $480,702
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
Tibor Kovacsovics, Md, MD
Hematology & Oncology — Payments: $245,023
Hematology & Oncology $245,023
John Godwin, Md, MD
Hematology & Oncology — Payments: $96,623
Hematology & Oncology $96,623
Dr. Rom Leidner, Md, MD
Hematology & Oncology — Payments: $79,796
Hematology & Oncology $79,796